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Exposure to estrogens is a risk factor for human breast can-
cer. Experiments on estrogen metabolism, formation of
DNA adducts, carcinogenicity, mutagenicity and cell
transformation led to and support the hypothesis that
reaction of specific estrogen metabolites, catechol estro-
gen-3,4-quinones, with DNA can generate the critical
mutations to initiate breast, prostate and other human
cancers. The major initiating pathway is illustrated in Fig-
ure 1. Estrone (E1) and estradiol (E2) can be metabolically
converted to 4-OHE1(E2) by cytochrome P450 (CYP)1B1.
Oxidation of these catechol estrogens leads to the corre-
sponding catechol estrogen-3,4-quinones, which can
react with DNA to form very small amounts of stable
adducts, which remain in DNA unless removed by repair,
and predominant amounts (99%) of depurinating
adducts, which detach from DNA, leaving behind apu-
rinic sites. Errors in the repair of these sites can lead to the
critical mutations that can initiate breast, prostate and
other human cancers.
Cancer biomarkers
The depurinating adducts are shed from cells and tissues
into the bloodstream and are excreted in urine. This
allows their identification and quantification as biomark-
ers of risk of developing breast, prostate and other human
cancers. High adduct levels have been detected in analysis
of urine and serum from women that are at high risk for
breast cancer or already have the disease. These analyses
are conducted by using ultraperformance liquid chroma-
tography/tandem mass spectrometry, a technology devel-
oped in our laboratory. In an initial study of such women,
highly significant differences were observed when urine
samples from normal-risk women were compared to
high-risk women or those with breast cancer. Similar
results were obtained in a second, larger study of women
with and without breast cancer and at high risk for the dis-
ease. In addition, analysis of urine samples from men
with and without prostate cancer showed that men with
the disease have relatively high levels of estrogen-DNA
adducts compared to men without prostate cancer. These
results have been confirmed in a second, larger study.
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Major metabolic pathway in cancer initiation by estrogens Figure 1
Major metabolic pathway in cancer initiation by 
estrogens.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Proceedings 2009, 3(Suppl 5):S8 http://www.biomedcentral.com/1753-6561/3/S5/S8
Page 2 of 2
(page number not for citation purposes)
Cancer prevention
Prevention of cancer arises from blocking the first critical
step in initiation, reaction of catechol estrogen quinones
with DNA. The most appropriate compounds for this task
include N-acetylcysteine (NAcCys), which blocks reaction
of the quinones with DNA by reacting with the quinones
and reducing the semiquinones back to catechols. In addi-
tion, NAcCys helps replenish the antioxidant glutathione
in cells. Resveratrol has the same chemical properties as
NAcCys in reducing the semiquinones to catechols, but
also induces the protective enzyme quinone reductase and
modulates the activating enzyme CYP1B1. When the
MCF-10F human breast epithelial cells were cultured in
the presence of 4-OHE2, and resveratrol and NAcCys were
added to the culture medium at different doses, the for-
mation of estrogen-DNA adducts by the cells was greatly
inhibited. These two antioxidants also inhibit the trans-
formation of MCF-10F cells and E6 mouse mammary cells
to malignant cells. The results of these studies suggest that
selected natural antioxidant compounds can reduce for-
mation of estrogen-DNA adducts, presumably decreasing
the risk of initiating and, thus, developing breast, prostate
and other human cancers.